Epkinly, Tepkinly(epcoritamab)
Epkinly, Tepkinly (epcoritamab) is an antibody pharmaceutical. Epcoritamab was first approved as Epkinly on 2023-05-19. It is used to treat large b-cell lymphoma diffuse in the USA. It has been approved in Europe to treat large b-cell lymphoma diffuse. It is known to target T-cell surface glycoprotein CD3 epsilon chain and B-lymphocyte antigen CD20.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Epkinly
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| epcoritamab | Biologic Licensing Application | 2023-05-16 |
| epkinly | Biologic Licensing Application | 2025-09-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| large b-cell lymphoma diffuse | — | D016403 | C83.3 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
50 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 4 | 18 | 3 | — | 2 | 24 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 5 | 17 | 3 | — | 2 | 23 |
| Follicular lymphoma | D008224 | — | C82 | 4 | 13 | 2 | — | 2 | 17 |
| B-cell lymphoma | D016393 | — | — | 5 | 14 | 1 | — | 1 | 17 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 5 | 11 | 2 | — | — | 15 |
| Neoplasms | D009369 | — | C80 | 1 | 3 | 2 | — | — | 6 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 2 | 8 | — | — | — | 9 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 5 | 6 | — | — | — | 7 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 3 | 6 | — | — | — | 6 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 1 | 2 | — | — | — | 3 |
| Reactive arthritis | D016918 | EFO_0007460 | M02.3 | 2 | 1 | — | — | — | 2 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | 1 | — | — | — | 1 |
| Hairy cell leukemia | D007943 | — | C91.4 | — | 1 | — | — | — | 1 |
| Residual neoplasm | D018365 | — | — | — | 1 | — | — | — | 1 |
| Waldenstrom macroglobulinemia | D008258 | — | C88.0 | — | 1 | — | — | — | 1 |
| Burkitt lymphoma | D002051 | — | C83.7 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aggression | D000374 | EFO_0003015 | — | 1 | — | — | — | — | 1 |
| Cytokine release syndrome | D000080424 | — | D89.83 | 1 | — | — | — | — | 1 |
| Syndrome | D013577 | — | — | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Epcoritamab |
| INN | epcoritamab |
| Description | Epcoritamab, sold under the brand name Epkinly, is a monoclonal antibody anticancer medication used for the treatment of diffuse large B-cell lymphoma. Epcoritamab is a bispecific CD20-directed CD3 T-cell engager. Epcoritamab was co-developed by AbbVie and Genmab.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 2134641-34-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4650393 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB16672 |
| UNII ID | D6OMY2L0WA (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CD3E
CD3E
MS4A1
MS4A1
Organism
Homo sapiens
Gene name
CD3E
Gene synonyms
T3E
NCBI Gene ID
Protein name
T-cell surface glycoprotein CD3 epsilon chain
Protein synonyms
CD3-epsilon, CD3e, CD3e antigen, epsilon polypeptide (TiT3 complex), CD3e molecule, epsilon (CD3-TCR complex), T-cell antigen receptor complex, epsilon subunit of T3, T-cell surface antigen T3/Leu-4 epsilon chain
Uniprot ID
Mouse ortholog
Cd3e (12501)
T-cell surface glycoprotein CD3 epsilon chain (P22646)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Epkinly – AbbVie
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 687 documents
View more details
Safety
Black-box Warning
Black-box warning for: Epcoritamab, Epkinly
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,567 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use